438
Participants
Start Date
May 20, 2019
Primary Completion Date
April 7, 2027
Study Completion Date
February 9, 2028
CC-99282
Specified dose on specified days
Rituximab
Specified dose on specified days
Obinutuzumab
Specified dose on specified days
Tafasitamab
Specified dose on specified days
Valemetostat
Specified dose on specified days
Local Institution - 703, Vienna
Local Institution - 254, Pilar
Local Institution - 601, Copenhagen
Local Institution - 902, Leuven
Local Institution - 704, Sankt Pölten
Local Institution - 701, Salzburg
Local Institution - 603, Vejle
Local Institution - 602, Aarhus
Local Institution - 503, Milan
Local Institution - 501, Bergamo
Local Institution - 506, Pavia
Local Institution - 302, Madrid
Local Institution - 304, Madrid
Local Institution - 303, Málaga
Local Institution - 408, Toulouse
Local Institution - 102, Tampa
Local Institution - 111, Jacksonville
Local Institution - 407, Bordeaux
Local Institution - 409, Montpellier
Local Institution - 305, Salamanca
Local Institution - 504, Bologna
Local Institution - 553, Busan
Local Institution - 151, Petah Tikva
Local Institution - 152, Ramat Gan
Local Institution - 107, Rochester
Local Institution - 406, Lille
Local Institution - 104, St Louis
Local Institution - 108, Overland Park
Local Institution - 402, Pierre-Bénite
Local Institution - 405, Paris
Local Institution - 404, Rouen
Local Institution - 101, Houston
Local Institution - 502, Napoli
Local Institution - 109, Scottsdale
Local Institution - 150, Jerusalem
Local Institution - 403, Créteil
Local Institution - 401, Villejuif
Local Institution - 653, Beijing
Local Institution - 662, Shenyang
Local Institution - 663, Shenyang
Local Institution - 650, Shanghai
Local Institution - 651, Tianjin
Local Institution - 660, Wuhan
Local Institution - 655, Zhengzhou
Local Institution - 659, Guangzhou
Local Institution - 657, Guangzhou
Local Institution - 452, São Paulo
Local Institution - 353, Santiago
Local Institution - 350, Santiago
Local Institution - 354, Santiago
Local Institution - 352, Santiago
Local Institution - 103, Hackensack
Local Institution - 255, Ciudad Autonoma de Buenos Aires
Local Institution - 253, Buenos Aires
Local Institution - 453, Porto Alegre
Local Institution - 450, São Paulo
Local Institution - 451, São Paulo
Local Institution - 201, Toronto
Local Institution - 355, Recoleta
Local Institution - 551, Seoul
Local Institution - 550, Seoul
Local Institution - 552, Seoul
Local Institution - 306, Badalona (Barcelona)
Local Institution - 301, Barcelona
Local Institution - 802, Edinburgh Scotland
Local Institution - 803, Southhampton
Lead Sponsor
Celgene
INDUSTRY